Dual-wheel drive, continuous dividend distribution, a leading company with tens of billions of assets increases investment in innovative drugs
Published Time:
2024-07-30
Surrounding Driven by a dual-engine strategy of "innovative drugs + high-end complex preparations," the well-known pharmaceutical company, HealthGen, is continuing to lead in the field of inhalation preparations. Furthermore, since its listing in 2001, HealthGen has maintained a stable dividend policy, having distributed cash dividends to shareholders 20 times, with a cumulative dividend amount exceeding 3.6 billion yuan.
Dual-engine drive
In recent years, HealthGen has implemented a dual-engine strategy of "innovative drugs + high-end complex preparations," increasing R&D investment, and focusing on key areas such as respiratory, tumor immunity, and mental health, forming a relatively clear product R&D pipeline.
In the field of respiratory preparations, since the launch of related products, the company's domestic market share has rapidly risen to the first echelon, becoming one of the most comprehensive enterprises in the domestic respiratory pipeline layout.
According to Zhao Fengguang, HealthGen's secretary to the board of directors, in terms of inhalation preparations, HealthGen currently has 10 products on the market and more than 20 respiratory products under development, successfully achieving coverage of all categories of asthma and COPD inhalation therapies for existing and under-development products.
In 2023, HealthGen's R&D expenses reached 1.662 billion yuan. The continuous high investment in R&D has yielded significant results for the company.
In terms of independent research and development, in recent years, the company has obtained approval for the listing of several blockbuster products, including Tobramycin Inhalation Solution, Salmeterol/Fluticasone Inhalation Powder, Tocilizumab Injection, and Curcumin Acetate Microspheres for Injection.
It is particularly worth mentioning that in 2022, HealthGen's independently developed improved new drug, Tobramycin Inhalation Solution (Jianketo®), was officially approved for listing, becoming the world's first inhalation drug for the treatment of bronchiectasis and the first inhaled antibiotic in China, effectively solving the problem of the lack of targeted drugs for bronchiectasis patients.
In BD, HealthGen focuses on advantageous therapeutic areas such as respiratory diseases, digestion, mental health, and assisted reproduction, continuously paying attention to international cutting-edge technologies and opportunities for international product layout, and introducing more innovative drug projects.
Among them, a drug for the treatment of influenza A and B in collaboration with Taijing Biology, TG-1000 capsules Phase III clinical trial has reached the primary endpoint, and the company is currently promoting the listing process of this drug.
Accelerating internationalization
Since the listing of GDR on the SIX Swiss Exchange in 2022, HealthGen has been accelerating the process of its internationalization strategy.
In 2023, HealthGen achieved overseas revenue of 2.584 billion yuan, accounting for 15.64% of the company's main business income. By the end of 2023, the company's products had been exported to more than 80 countries and regions in Asia, Europe, North America, and Africa. A total of 18 raw materials and intermediates have passed international certification on-site inspections, and 35 international certification certificates with valid periods have been obtained.
According to Zhao Fengguang, in addition to maintaining the existing advantages in raw material exports, the company is also actively promoting the overseas planning and strategy of key preparation products.
In 2023, the company obtained 4 approvals and submitted 14 new registrations for chemical preparations in overseas markets. Among them, Compound Ipratropium Bromide Solution completed registration review in the Philippines and obtained a registration certificate in January 2024; Levosalbutamol Hydrochloride Nebulization Solution submitted a registration application in Macao and obtained a registration certificate in February 2024; and 西曲瑞克醋酸注射液 has submitted a registration application to the United States. In addition, the company is actively developing the international business of preparation products, and the sales and registration of respiratory and assisted reproductive products in countries such as Pakistan, Indonesia, the Philippines, and Vietnam are ongoing." Zhao Fengguang said.
Zhao Fengguang stated that in the future, the company will continue to deepen cooperation with global strategic customers, actively promote the international registration and certification of products, increase the market development efforts of advantageous products, further improve the overseas market share, and promote the high-quality and sustainable development of the group.
Cumulative dividend exceeding 3.6 billion yuan
In December 2023, the China Securities Regulatory Commission issued "Supervisory Guidance No. 3 for Listed Companies—Cash Dividends of Listed Companies," further clarifying the encouragement of cash dividends and promoting the improvement of dividend levels.
In April 2024, the capital market's new "Nine Articles" proposed "strengthening the supervision of cash dividends of listed companies," "increasing incentives for companies with high-quality dividends, and taking multiple measures to promote higher dividend yields," and "enhancing the stability, sustainability, and predictability of dividends."
In recent years, while achieving steady development of its main business, HealthGen has continuously rewarded investors through cash dividends and share buybacks.
In 2023, HealthGen planned to distribute cash dividends of 1.80 yuan (including tax) per 10 shares. Adding the 475 million yuan repurchase amount in 2023, the company's total cash dividend amounted to 56.22% of the net profit attributable to shareholders of the listed company in the reporting period.
Not only that, since its listing, HealthGen has maintained a stable dividend policy.
According to Zhao Fengguang, as of now, the company has distributed cash dividends to shareholders 20 times, with a cumulative dividend amount exceeding 3.6 billion yuan.
In addition, in recent years, the company has completed multiple secondary market repurchases, with cumulative repurchase funds exceeding 2 billion yuan. The vast majority of repurchased shares have been cancelled, demonstrating the company's emphasis on shareholder interests and the board of directors' and management's firm confidence in the company's intrinsic value and future development.
This article is from: China Fund News